Latest abdominal pain Stories
-- Primary endpoint was met for 50 mg twice daily dosing -- FREMONT, Calif., Oct. 1, 2014 /PRNewswire/ -- Ardelyx, Inc.
--Use of Crowdsourced Clinical Trial Protocols and Telemonitoring for Remote Patient Data Collection Is Potential Game-Changer for Orphan Diseases NEW YORK, Sept.
Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Sept. 18, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc.
-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept.
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
- Potential Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) in Men and Women Granted Priority Review Status - DUBLIN, Sept.
DUBLIN, Ireland, August 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jjj5vs/global_peptic) has announced the addition of the
Genetic changes that occur in patients with the bowel condition Crohn's disease could hold clues to fighting the illness.
At Weinberg Gastrointestinal, patients can now receive both American and Canadian screening colonoscopies in Gilbert, Arizona GILBERT, Ariz., Aug.
- Withering but not falling off, as a blossom that persists on a twig after flowering.